Pharmaceutical Technology on MSN
FDA approves Acadia’s Daybue Stix for Rett syndrome
The US Food and Drug Administration has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide), a dye and ...
Although renowned for dozens of spectacular peaks, Acadia National Park on Mount Desert Island has more than outstanding ...
Acadia Pharmaceuticals Inc. is rated a Buy for its steady NUPLAZID/DAYBUE franchises & pipeline-driven upside potential. Read ...
Acadia Healthcare stock fell after revising its 2025 outlook due to higher litigation costs stemming from patient-related lawsuits.
Camping Kiddos on MSN
The ultimate Acadia National Park itinerary for a 1-4 day visit
Are you looking to plan your perfect Acadia National Park itinerary but don’t know where to start? Well, you’ve come to the ...
ACADIA Pharmaceuticals generates revenue primarily through the commercialization of NUPLAZID for Parkinson's disease ...
We bought a 2024 GMC Acadia Elevation AWD for $49,190—anonymously from an area dealer, as we do with every vehicle we ...
16d
Bar Harbor businesses fear economic hit as Acadia National Park adds $100 fee for non-US tourists
A new $100 surcharge for non-U.S. visitors to Acadia and other national parks raises alarm among Bar Harbor businesses. BAR HARBOR, Maine — Starting next year, non-U.S. residents will need to pay an ...
Friends of Acadia estimates the park lost about $1.75M in entry revenue in October 2025 alone, not to mention the first two weeks of November, which were also in shutdown.
Acadia Healthcare faces rising legal, insurance, and compliance costs and a Medicaid-heavy payer mix under policy pressure.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback